Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Pediatrics Reports
Erschienen in: Current Pediatrics Reports 2/2015

01.06.2015 | Hematology/Oncology (C Cole, Section Editor)

Hematopoietic Cell Transplantation and Sickle-Cell Disease: An Option for Everyone?

verfasst von: Justine Kahn, Elana Smilow, Monica Bhatia

Erschienen in: Current Pediatrics Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

There have been vast improvements in the care of patients with sickle-cell disease (SCD) such that patients are now surviving four times longer today than in the 1970s. This is largely due to improvements in supportive care therapies such as infection prophylaxis, vaccinations, and better pain management strategies. Hematopoietic cell transplantation (HCT) affords patients with SCD the only curative treatment and is usually reserved only for the most symptomatic of patients who have matched sibling donors. As more is learned about the natural progression of this disease, there has been a push toward modifying conditioning regimens to decrease regimen-related toxicities such that all patients with matched sibling donors can be offered this option. In this article, we review the current state of HCT in patients with SCD and the progress that has been made in an attempt to render this treatment as an option for all patients afflicted with this condition.
Literatur
1.
McGann PT. Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality. J Pediatr. 2014;165:18–22.CrossRefPubMed
2.
Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Arch Dis Child. 2015;100:48–53.CrossRefPubMedCentralPubMed
3.
• Shenoy S. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol. 2013;4:335–44. This paper was important in that it helped to highlight the current advances in Stem Cell Transplantation including advances in sibling donor transplants, unrelated transplants, and haploidentical transplants. It also discussed current indications for transplant.
4.
Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 2005;84:363–76.CrossRefPubMed
5.
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312:1033–48. This paper focused on the treatment options for Sickle Cell Disease focusing primarily on medical treatments without mentioning Stem Cell Transplant as a viable option, highlighting the need to improve awareness of this therapeutic modality.
6.
Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–44.CrossRefPubMed
7.
8.
Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014;89:530–5.CrossRefPubMedCentralPubMed
9.
Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550–4.PubMed
10.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New Engl J Med. 1998;339:5–11.CrossRefPubMed
11.
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New Engl J Med. 1995;332:1317–22.CrossRefPubMed
12.
Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88:932–8.CrossRefPubMed
13.
Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT 3rd. Bone-marrow transplantation in a patient with sickle-cell anemia. New Engl J Med. 1984;311:780–3.CrossRefPubMed
14.
Bernaudin F, Sfgm TC. Stem cell transplantation in sickle cell disease: results, perspectives. Arch Pediatr. 2008;15:633–5.CrossRefPubMed
15.
Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137:479–85.CrossRefPubMed
16.
Hoppe CC, Walters MC. Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol. 2001;13:85–90.CrossRefPubMed
17.
Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918–24.PubMed
18.
Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22:1–6.CrossRefPubMed
19.
Quinn CT, Lee NJ, Shull EP, Ahmad N, Rogers ZR, Buchanan GR. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111:544–8.CrossRefPubMedCentralPubMed
20.
Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. New Engl J Med. 1996;335:369–76.CrossRefPubMed
21.
Walters MC, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant. 2001;7:665–73.CrossRefPubMed
22.
Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant. 2005;35:171–7.CrossRefPubMed
23.
Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant. 2003;9:519–28.CrossRefPubMed
24.
Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. New Engl J Med. 2009;361:2309–17.CrossRefPubMedCentralPubMed
25.
Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008;14:1270–8.CrossRefPubMed
26.
Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49:913–20.CrossRefPubMed
27.
Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013;90:308–12.CrossRefPubMed
28.
• Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematol Am Soc Hematol Educ Program. 2013;2013:370–6. Reviewed the novelty of haploidentical stem cell transplantation and its utility in Sickle Cell Disease, highlighting outcomes. One of the first papers highlighting this treatment route.
29.
Locatelli F, Rocha V, Reed W, et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood. 2003;101:2137–43.CrossRefPubMed
30.
Boncimino A, Bertaina A, Locatelli F. Cord blood transplantation in patients with hemoglobinopathies. Transfus Apher Sci. 2010;42:277–81.CrossRefPubMed
31.
Bolanos-Meade J, Brodsky RA. Blood and marrow transplantation for sickle cell disease: is less more? Blood Rev. 2014;28:243–8.CrossRefPubMed
32.
• Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18:1265–72. Highlighted the multi-center trial evaluating the role of unrelated cord blood transplants in patients with sickle cell disease.
33.
Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant. 2007;11:641–4.CrossRefPubMed
34.
Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant. 2011;17:1375–82.CrossRefPubMedCentralPubMed
35.
• Radhakrishnan K, Bhatia M, Geyer MB, et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant. 2013;19:676–7. Highlighted the multi-center trial evaluating the role of unrelated cord blood transplants in patients with sickle cell disease.
36.
Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. New Engl J Med. 2014;371:339–48.CrossRefPubMed
37.
Munchel AT, Kasamon YL, Fuchs EJ. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol. 2011;24:359–68.CrossRefPubMedCentralPubMed
38.
Brodsky RA, Luznik L, Bolanos-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42:523–7.CrossRefPubMedCentralPubMed
39.
• Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285–91. As with the reference above, the paper reviewed haploidentical Stem Cell Transplantation in this patient population with a newer modality of using post transplant cyclophosphamide and its efficacy.
40.
• Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013;19:820–30. Contrasted the above paper in that the approach was using a CD34 selected approach rather than post transplant cyclophosphamide and focused on long terms outcomes after transplant in these patients.
41.
Verlinsky Y, Rechitsky S, Schoolcraft W, Strom C, Kuliev A. Preimplantation diagnosis for Fanconi anemia combined with HLA matching. JAMA. 2001;285:3130–3.CrossRefPubMed
42.
• Kahraman S, Beyazyurek C, Yesilipek MA, et al. Successful haematopoietic stem cell transplantation in 44 children from healthy siblings conceived after preimplantation HLA matching. Reprod Biomed Online. 2014;29:340–51. Reviewed the efficacy of pre-implantation HLA matching in patients undergoing HCT.
43.
Morgan ER, Girod J, Rinehart JS. Having a child to save a sibling: reassessing risks and benefits of creating stem cell donors. Pediatr Blood Cancer. 2007;48:249–53.CrossRefPubMed
44.
Romero Z, Urbinati F, Geiger S, et al. β-Globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest. 2013;pii:67930.
45.
Platt OS, Guinan EC. Bone marrow transplantation in sickle cell anemia–the dilemma of choice. New Engl J Med. 1996;335:426–8.CrossRefPubMed
46.
Nickel RS, Hendrickson JE, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with “less severe” sickle cell disease. Blood. 2014;124:861–6.CrossRefPubMed
47.
Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2010;16:263–72.CrossRefPubMedCentralPubMed
48.
Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 2008;41:109–17.CrossRefPubMed
Metadaten
Titel
Hematopoietic Cell Transplantation and Sickle-Cell Disease: An Option for Everyone?
verfasst von
Justine Kahn
Elana Smilow
Monica Bhatia
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Pediatrics Reports / Ausgabe 2/2015
Elektronische ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-015-0079-7

Weitere Artikel der Ausgabe 2/2015

Current Pediatrics Reports 2/2015 Zur Ausgabe

Hematology/Oncology (C Cole, Section Editor)

Survival and Quality of Life Following Treatment for Sarcoma

Hematology/Oncology (C Cole, Section Editor)

Recent Advances in Haemophilia Management

Hematology/Oncology (C Cole, Section Editor)

Infectious Prophylaxis in Paediatric Oncology and Stem Cell Transplantation

Hematology/Oncology (C Cole, Section Editor)

Childhood Acute Lymphoblastic Leukemia: Toward Personalized Medicine

Endocrine (M Craig, Section Editor)

Diabetes Complications in Childhood Diabetes: New Biomarkers and Technologies

Hematology/Oncology (C Cole, Section Editor)

The Role of Registries and Tumor Banking in Rare Pediatric Tumors

Neu im Fachgebiet Pädiatrie

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

16.05.2024 Arterielle Hypertonie in der Pädiatrie Nachrichten

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise